Kevin R. Sayer - 08 Mar 2026 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
Executive Chair, Director
Signature
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Kevin R. Sayer
Issuer symbol
DXCM
Transactions as of
08 Mar 2026
Net transactions value
$0
Form type
4
Filing time
10 Mar 2026, 16:02:03 UTC
Previous filing
02 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SAYER KEVIN R Executive Chair, Director 6340 SEQUENCE DRIVE, SAN DIEGO /s/ Jereme M. Sylvain, as Attorney-in-Fact for Kevin R. Sayer 10 Mar 2026 0001286858

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Award +32,749 +8% $0.000000* 441,739 08 Mar 2026 Direct F1
transaction DXCM Common Stock Tax liability -32,498 -7.4% $68.10* 409,241 08 Mar 2026 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting on the one year anniversary of the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2 Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person.
F3 Included in this number are 106,972 unvested RSUs, 32,749 of which were granted on March 8, 2026 and shall vest on March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.